Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
XRTX
Upturn stock ratingUpturn stock rating

XORTX Therapeutics Inc (XRTX)

Upturn stock ratingUpturn stock rating
$0.89
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: XRTX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $14.52

1 Year Target Price $14.52

Analysts Price Target For last 52 week
$14.52 Target price
52w Low $0.66
Current$0.89
52w High $2.98

Analysis of Past Performance

Type Stock
Historic Profit -22.71%
Avg. Invested days 21
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.64M USD
Price to earnings Ratio -
1Y Target Price 14.52
Price to earnings Ratio -
1Y Target Price 14.52
Volume (30-day avg) 1
Beta -0.03
52 Weeks Range 0.66 - 2.98
Updated Date 08/15/2025
52 Weeks Range 0.66 - 2.98
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.1

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -36.5%
Return on Equity (TTM) -37.96%

Valuation

Trailing PE -
Forward PE 0.96
Enterprise Value 2592208
Price to Sales(TTM) -
Enterprise Value 2592208
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.09
Shares Outstanding 5212220
Shares Floating 3680963
Shares Outstanding 5212220
Shares Floating 3680963
Percent Insiders 2.63
Percent Institutions 3.52

ai summary icon Upturn AI SWOT

XORTX Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing therapies to treat progressive kidney disease, with a focus on rare diseases. Founded with the goal of addressing unmet medical needs in kidney health, the company has advanced several clinical programs targeting specific genetic or disease-related causes of kidney dysfunction.

business area logo Core Business Areas

  • Drug Development: Focuses on researching, developing, and commercializing pharmaceutical products for kidney diseases.
  • Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of XORTX's drug candidates.
  • Intellectual Property: Securing patents and maintaining intellectual property rights related to its drug candidates.

leadership logo Leadership and Structure

Dr. Allen Nissenson, Chief Medical Officer, leads clinical development. Other key personnel include a management team focused on clinical, regulatory, and financial aspects of the company. Organizational structure consists of departments focused on research and development, clinical operations, regulatory affairs, and finance.

Top Products and Market Share

overview logo Key Offerings

  • XRx-008 (Oxipurinol): A hypoxanthine oxidase inhibitor being developed for autosomal dominant polycystic kidney disease (ADPKD) and COVID-19 related Acute Kidney Injury. There is no market share data currently. Major competitors in the ADPKD space are Tolvaptan (Otsuka Pharmaceutical) and other therapies in development.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry focused on kidney diseases is characterized by high unmet needs, significant research activity, and potential for innovation. Companies are focusing on developing targeted therapies for specific kidney disorders, addressing the limitations of existing treatments.

Positioning

XORTX Therapeutics Inc. is positioned as a company developing novel therapies for progressive kidney disease, particularly in areas with limited treatment options. Its competitive advantage lies in its focus on specific genetic and disease-related targets and its potential to develop first-in-class therapies.

Total Addressable Market (TAM)

The total addressable market (TAM) for ADPKD therapies is estimated to be in the billions of dollars. XORTX Therapeutics Inc. is positioned to capture a portion of this market with its XRx-008 drug candidate, contingent upon successful clinical trials and regulatory approval.

Upturn SWOT Analysis

Strengths

  • Focus on unmet needs in kidney disease
  • Proprietary drug development platform
  • Experienced management team
  • Potential for first-in-class therapies

Weaknesses

  • Limited financial resources
  • Dependence on clinical trial outcomes
  • No currently approved products
  • High regulatory hurdles

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new kidney disease indications
  • Advancements in biomarker development
  • Regulatory pathways for orphan drugs

Threats

  • Competition from established pharmaceutical companies
  • Failure of clinical trials
  • Adverse regulatory decisions
  • Economic downturn affecting investment in biotech

Competitors and Market Share

competitor logo Key Competitors

  • OTSU

Competitive Landscape

XORTX Therapeutics Inc. faces competition from established pharmaceutical companies with approved therapies for kidney diseases and from other biotech companies developing novel treatments. XORTX's advantage lies in its focus on specific genetic and disease-related targets.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been characterized by advancement of clinical programs and securing funding for research and development.

Future Projections: Future growth is dependent on clinical trial outcomes, regulatory approvals, and commercialization of its drug candidates. Analyst estimates vary and depend on these factors.

Recent Initiatives: Recent initiatives include advancing XRx-008 into later-stage clinical trials and exploring new partnerships.

Summary

XORTX Therapeutics Inc. is a development-stage biopharmaceutical company focusing on kidney diseases. Its strength lies in its pipeline of novel therapies and a focus on unmet needs. The company's success depends on the outcomes of its clinical trials and regulatory approvals. XORTX is dependent on a number of key clinical trials in their pipeline. It needs to expand it's pipeline to include other therapies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About XORTX Therapeutics Inc

Exchange NASDAQ
Headquaters Calgary, AB, Canada
IPO Launch date 2018-11-28
Founder, CEO, President & Director Dr. Allen Warren Davidoff Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.